勘误：CDK4/6抑制剂可提高乐伐替尼对肝癌细胞的抗肿瘤疗效。
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.
作者信息
Digiacomo Graziana, Fumarola Claudia, La Monica Silvia, Bonelli Mara, Cavazzoni Andrea, Galetti Maricla, Terenziani Rita, Eltayeb Kamal, Volta Francesco, Zoppi Silvia, Bertolini Patrizia, Missale Gabriele, Alfieri Roberta, Petronini Pier Giorgio
机构信息
Department of Medicine and Surgery, University of Parma, Parma, Italy.
Department of Occupational and Environmental Medicine, Epidemiology and Hygiene, INAIL - Italian Workers' Compensation Authority, Rome, Italy.
出版信息
Front Oncol. 2024 Dec 6;14:1532291. doi: 10.3389/fonc.2024.1532291. eCollection 2024.
Abstract
[This corrects the article DOI: 10.3389/fonc.2022.942341.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fonc.2022.942341。]
相似文献
1
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.勘误：CDK4/6抑制剂可提高乐伐替尼对肝癌细胞的抗肿瘤疗效。
Front Oncol. 2024 Dec 6;14:1532291. doi: 10.3389/fonc.2024.1532291. eCollection 2024.
2
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂可提高乐伐替尼在肝癌细胞中的抗肿瘤疗效。
Front Oncol. 2022 Jul 22;12:942341. doi: 10.3389/fonc.2022.942341. eCollection 2022.
3
Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.勘误：经动脉化疗栓塞联合乐伐替尼与经动脉化疗栓塞联合索拉非尼治疗不可切除肝细胞癌的系统评价和荟萃分析。
Front Oncol. 2023 Jun 22;13:1233247. doi: 10.3389/fonc.2023.1233247. eCollection 2023.
4
Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma.勘误：优化乐伐替尼与帕博利珠单抗联合用于晚期子宫内膜癌患者的治疗
Front Oncol. 2023 Aug 7;13:1232476. doi: 10.3389/fonc.2023.1232476. eCollection 2023.
5
[Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].[细胞周期蛋白依赖性激酶4和6选择性抑制剂阿贝西利在激素受体阳性乳腺癌中的药理作用]
Gan To Kagaku Ryoho. 2019 Sep;46(9):1405-1411.
6
Corrigendum: Real-World Lenvatinib Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.勘误：晚期肝细胞癌患者中乐伐替尼与索拉非尼的真实世界研究：一项倾向评分匹配分析。
Front Oncol. 2021 Dec 14;11:823960. doi: 10.3389/fonc.2021.823960. eCollection 2021.
7
CDK4/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer.细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂阿贝西利联合低剂量放疗，通过使Rb基因缺陷型小细胞肺癌的肿瘤微环境炎症化，增强对程序性死亡受体1（PD-1）阻断的抗肿瘤免疫反应。
Transl Lung Cancer Res. 2024 May 31;13(5):1032-1046. doi: 10.21037/tlcr-24-33. Epub 2024 May 21.
8
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.勘误：晚期肾细胞癌患者的3期CLEAR研究：乐伐替尼联合帕博利珠单抗组和舒尼替尼组亚组的结果
Front Oncol. 2024 Mar 1;13:1343027. doi: 10.3389/fonc.2023.1343027. eCollection 2023.
9
YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS.YRDC 通过调节 KRAS 的翻译介导肝癌细胞对乐伐替尼的耐药性。
Front Pharmacol. 2021 Oct 1;12:744578. doi: 10.3389/fphar.2021.744578. eCollection 2021.
10
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.勘误：转移性子宫内膜癌的管理：检查点抑制剂获批后一线治疗之外医生的选择
Front Oncol. 2024 Jan 22;13:1357793. doi: 10.3389/fonc.2023.1357793. eCollection 2023.
Zotero 插件